

Dear Author,


Please, note that changes made to the HTML content will be added to the article before publication, but are not reflected in this PDF.

Note also that this file should not be used for submitting corrections.



Contents lists available at ScienceDirect

## Neuropeptides

journal homepage: [www.elsevier.com/locate/ynpep](http://www.elsevier.com/locate/ynpep)

## Q2 Development of neuropeptide Y-mediated heart innervation in rats

Q3 Petr M. Masliukov<sup>a,\*</sup>, Konstantin Moiseev<sup>a</sup>, Andrey I. Emanuilov<sup>a</sup>, Tatyana A. Anikina<sup>b</sup>, Alexey A. Zverev<sup>b</sup>, Alexandr D. Nozdrachev<sup>c</sup><sup>a</sup> Department of Normal Physiology, Yaroslavl State Medical University, ul. Revoliucionnaya, 5, Yaroslavl 150000, Russia<sup>b</sup> Department of Anatomy, Physiology and Healthcare, Kazan (Volga Region) Federal University, Kremlyovskaya St. 18, Kazan 420008, Russia<sup>c</sup> Department of Physiology, Saint Petersburg State University, Universitetskaya nab., 7–9, Saint-Petersburg 199034, Russia

## ARTICLE INFO

## Article history:

Received 9 July 2015

Received in revised form 10 October 2015

Accepted 11 October 2015

Available online xxxx

## Keywords:

Neuropeptide Y

Receptors

Autonomic nervous system

Heart innervation

Intramural ganglia

Development

Immunohistochemistry

Western blot analysis

## ABSTRACT

Neuropeptide Y (NPY) plays a trophic role in the nervous and vascular systems and in cardiac hypertrophy. However, there is no report concerning the expression of NPY and its receptors in the heart during postnatal development. In the current study, immunohistochemistry and Western blot analysis was used to label NPY, and Y1R, Y2R, and Y5R receptors in the heart tissue and intramural cardiac ganglia from rats of different ages (newborn, 10 days old, 20 days old, 30 days old, 60 days old, 1 year old, and 2 years old).

The obtained data suggest age-dependent changes of NPY-mediated heart innervation. The density of NPY-immunoreactive (IR) fibers was the least in newborn animals and increased in the first 20 days of life. In the atria of newborn and 10-day-old rats, NPY-IR fibers were more abundant compared with the ventricles. The vast majority of NPY-IR fibers also contained tyrosine hydroxylase, a key enzyme in catecholamine synthesis. The expression of Y1R increased between 10 and 20 days of life. Faint Y2R immunoreactivity was observed in the atria and ventricles of 20-day-old and older rats. In contrast, the highest level of the expression of Y5R was found in newborn pups comparing with more adult rats. All intramural ganglionic neurons were also Y1R-IR and Y5R-IR and Y2R-negative in all studied animals.

Thus, the increasing of density of NPY-containing nerve fibers accompanies changes in relation of different subtypes of NPY receptors in the heart during development.

© 2015 Published by Elsevier Ltd.

## 1. Introduction

Neuropeptide Y (NPY) is a 36-amino acid peptide, including five tyrosine residues on each molecule and a C terminal amide structure (Tatemoto 1982; Tatemoto et al. 1982). NPY is widely distributed in both the central and peripheral nervous systems and has been functionally related to regulation of blood pressure, circadian rhythms, feeding behavior, anxiety, memory processing, and cognition in the CNS and to vasoconstriction and gastrointestinal tract motility in the PNS (Hodges et al. 2009; Nozdrachev and Masliukov 2011; Kageyama et al. 2012; Masliukov and Nozdrachev 2013).

The various biological effects of NPY and its homologs are mediated by the activation of at least five receptors, known as the Y1R, Y2R, Y4R, Y5R, and Y6R. Among the six NPY receptor subtypes, Y3R subtype has not been cloned, Y4R subtype reacts with pancreatic polypeptide (PP), and Y6R is a nonfunctional receptor in rat and human (Balasubramaniam 1997). Therefore, it seems that Y1R, Y2R, and Y5R are the three major subtypes of NPY receptors that mediate the biological functions of NPY in human and rat. All known NPY

receptors belong to the large superfamily of G-protein-coupled, heptahelical receptors (Walther et al. 2011). Actions of NPY on peripheral target-organs are predominantly realized through postsynaptic Y1R, Y5R, and presynaptic Y2R (Balasubramaniam 1997; Michel et al. 1998; Hu et al., 2014).

In the heart, the most prominent source of NPY is postganglionic sympathetic fibers, the majority originating from neurons located in the stellate ganglion (Richardson et al. 2006; Masliukov et al. 2012). In rodents, NPY is also expressed by the parasympathetic neurons of the intrinsic cardiac ganglia (Richardson et al. 2003). Sensory neurons do not produce NPY under physiological conditions (Wakisaka et al. 1991; Valder et al. 2003; Chottová Dvoráková et al. 2008).

NPY can both decrease and increase the contractile response of electrically stimulated rat ventricular cardiomyocytes (Piper et al. 1989; Millar et al. 1991; Allen et al. 2006). The two opposing inotropic effects of NPY in adult rat cardiac myocytes are mediated by different NPY receptor subtypes: positive effects by Y1R and negative effects by Y2R (Protas et al. 2003).

The negative effect, observed in isoproterenol-treated cells, is due primarily to stimulation of the transient outward current ( $I_{to}$ ) and mediated through an inhibitory G protein/adenylate cyclase pathway (Kassis et al. 1987; Piper et al. 1989; Millar et al. 1991). NPY also activates the slow inward L-type  $Ca^{2+}$  current ( $I_{CaL}$ ) and therefore

\* Corresponding author at: Department of Normal Physiology and Biophysics, Yaroslavl State Medical Academy, Revoliucionnaya 5, Yaroslavl 150000, Russia  
E-mail address: [mpm@yma.ac.ru](mailto:mpm@yma.ac.ru) (P.M. Masliukov).

increases the contraction of the cell. NPY may affect heart rate by decreasing  $I_f$  (Protas et al. 2003).

NPY may play an important developmental role by promoting growth and/or differentiation of a variety of cells in a receptor-specific manner. Via its Y1R, Y2R, and Y5R, NPY promotes angiogenesis and preadipocyte differentiation (Kuo et al. 2007; Parker and Balasubramaniam 2008; Zhang et al. 2015). NPY has been shown to be a potent, multifunctional angiogenic factor, which stimulates proliferation, migration, and capillary tube formation in endothelial cells. NPY is angiogenic at concentrations below those required for vasoconstriction (Zukowska-Grojec et al. 1998).

NPY is also associated with cardiac hypertrophy. NPY produces hypertrophy by increasing protein synthesis. The effect is age dependent, with a maximum (20% increase of de novo protein synthesis) observed in cells from 16-week-old animals. Experiments using selective NPY agonists and antagonists suggest that the hypertrophic effect of NPY in cardiac myocytes isolated from spontaneously hypertensive rats is mediated by Y5R (Pellieux et al. 2000).

The expression of the spectrum of neurotransmitters in autonomic ganglionic neurons is subject to changes during pre- and postnatal development (Apostolova and Dechant, 2009, Young et al. 2011; Masliukov et al. 2012, 2015). Sympathetic NPY-immunoreactive (IR) nerve fibers show the earliest expression by 16 days of rat gestation in myocardium (Shoba and Tay 2000). However, NPY-IR nerve fiber densities are low at birth. Densities increase during first 2 weeks of postnatal life and then remain relatively stable until adulthood. Later, developing nerve fibers in the atria of young rats express abundant NPY and this fact would suggest that the peptide may play a trophic role in the development of specialized cardiomyocytes (Nyquist-Battie et al. 1994).

The purpose of this study was to investigate the developmental changes of NPY-IR structures (nerve fibers and intramural ganglionic neurons), Y1R, Y2R, and Y5R in the heart of rats of different ages from newborn through senescence using immunohistochemistry and Western blot analysis.

## 2. Materials and methods

### 2.1. Experimental animals

All animal procedures were approved by the Institutional Animal Care and Use Committee of the Yaroslavl State Medical University and were conducted in accordance with the "Guide for the Care and Use of Laboratory Animals" (NIH Publication No. 85-23, revised 1996) as well as the relevant Guidelines of the Russian Ministry of Health for scientific experimentation on animals.

Newborn, 10-day-old, 20-day-old, 30-day-old, 2-month-old, 1-year-old, and 2-year-old Wistar rats ( $2 \times 7$  groups each containing 5 animals) were used in this work to label NPY and Y1R, Y2R, Y5R in the heart tissue by immunohistochemistry and Western blot analysis.

All animals were kept in acrylic cages with wood shavings in an acclimatized room (12/12 h light/dark cycle;  $22 \pm 3$  °C) and were provided with water and pellets ad libitum.

### 2.2. Tissue preparation

All animals were killed with a lethal dose of sodium pentobarbital (Nembutal®, 300 mg/kg, i.p.), after which they were perfused transcardially with 20 ml (newborn and 10 days old), 100 ml (20 and 30 days old), or 500 ml (2 months old and older) of physiological saline and 1 µl heparin followed by a similar volume of fixative composed of 4% paraformaldehyde (PF) in 0.1 M phosphate buffer. After perfusion, the right and left ventricles and the atria were dissected out, rinsed in physiological solution, and immersed in 4% PF for 1–2 h at room temperature. Following fixation, they were washed in three 30-min changes of phosphate-buffered saline (PBS; 0.01 M; pH 7.4), cryoprotected by

overnight immersion in 20% buffered (pH 7.4) sucrose solution at 4 °C, and mounted in TissueTek (Sakura Finetek Europe, Zoeterwoude, The Netherlands) on a cryostat chuck and frozen. Twelve-micrometer-thick cross sections were cut with a cryostat, mounted on poly-L-lysine-coated slides, and air-dried for 1 h.

### 2.3. Western blot analysis

Samples from heart tissues were homogenized with a lysis buffer (20 mM Tris HCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, protease inhibitor cocktail (Sigma)). The concentration of the total proteins was determined in all lysed tissues using the Bradford reagent (Fermentas, USA). Each tissue lysate was diluted in sample buffer (Bio-Rad Laboratories Inc., USA) and denatured at 95 °C for 5 min. An equivalent amount of samples were loaded and separated by 10% polyacrylamide gel electrophoresis and transferred to PVDF transfer membranes (AppliChem, Germany). Membranes were blocked with a blocking solution containing 3% non-fat dry milk (AppliChem, Germany) in TBS-T (0.1% Tween 20, 0.2 mM Tris, 137 mM NaCl) for 30 min at room temperature. After washing with TBS-T, membranes were incubated with primary antibodies (rabbit anti-Y1R, 1:1000, Abcam, ab73897, UK; rabbit anti-Y2R, 1:500, Santa Cruz, H-147, USA; rabbit anti-Y5R, 1:10,000, Abcam, ab 133,757, UK; rabbit anti-GAPDH (Glyceraldehyde 3-phosphate dehydrogenase), 1:2500, Abcam, ab9485, UK) diluted in same the blocking solution at 4 °C overnight. Following washing with TBS-T, membranes were incubated with secondary antibodies (goat HRP-conjugated anti-rabbit IgG, Abcam, ab6721) at 1:3000. The immunoblots were detected by chemiluminescence (ECL Prime Western blotting detection reagent, BioRad) with a Syngene G:BOX Chemi XR5E imaging system (Syngene, UK). Chemiluminescent signals were quantified with Gene Tools Gel Analysis software (Syngene, UK), and expressed relative to GAPDH. Protein molecular weight markers were included in each Western blot analysis.

### 2.4. Immunohistochemistry

Serial sections of the heart tissue were processed for the immunohistochemistry. The sections were preincubated for 30 min at room temperature with the blocking buffer containing 5% normal donkey serum (Jackson ImmunoResearch Laboratories, USA) and 0.3% Triton X-100 (Sigma, USA) in PBS to prevent non-specific binding of secondary antibodies. In order to visualize NPY, Y1R, Y2R, Y5R, tyrosine hydroxylase (TH), choline acetyltransferase (ChAT), and single or double immunostaining with antibodies (raised in different host species; see Table 1a)

**Table 1**

a) Primary antisera used for immunohistochemistry				Q1
Primary antisera	Host species	Dilution	Source	
NPY	Sheep	1:500	Abcam, ab6173	t1.2
NPY	Rabbit	1:500	Abcam, ab43871	t1.3
PGP9.5	Rabbit	1:200	Abcam, ab10404	t1.4
TH	Sheep	1:1000	Abcam, ab113	t1.5
ChAT	Goat	1:50	Millipore, AB144P	t1.6
Y1R	Rabbit	1:500	Abcam, ab73897	t1.7
Y2R	Rabbit	1:500	Santa Cruz, H-147	t1.8
Y5R	Rabbit	1:500	Abcam, ab133757	t1.9
b) Secondary antisera used for immunohistochemistry				
Secondary antisera	Dilution	Source		
Donkey anti-goat IgG FITC	1:200	Jackson ImmunoResearch		t1.10
Donkey anti-rabbit IgG FITC	1:200	Jackson ImmunoResearch		t1.11
Donkey anti-rabbit IgG CY3	1:200	Jackson ImmunoResearch		t1.12
Donkey anti-sheep IgG FITC	1:200	Jackson ImmunoResearch		t1.13
Donkey anti-sheep IgG CY3	1:200	Jackson ImmunoResearch		t1.14
CY3—cyanine 3, FITC—fluorescein isothiocyanate.				t1.15

186 was performed. Antibodies to PGP9.5 were used in to label the neuronal  
187 cell bodies in the intramural ganglia.

188 Subsequently, the sections were incubated in the primary antisera  
189 for 24 h at room temperature, rinsed in PBS and further incubated in  
190 the corresponding secondary antisera for 2 h at room temperature  
191 (see Table 1b). The sections were then rinsed three final times in PBS,  
192 mounted on glass slides, allowed to dry overnight and coverslipped  
193 using VectaShield (Vector Bioproducts, USA). The control experiments  
194 were carried out with the primary antibody replaced with NDS.

## 195 2.5. Image processing and statistics

196 The specimens were examined using an Olympus BX43 fluorescence  
197 microscope (Tokyo, Japan) fitted with filter sets that allowed separate  
198 visualization of FITC or CY3. Images from the fluorescence microscope  
199 were recorded using a TCH 5.0 cooled CCD digital camera and ISCapture  
200 version 3.6 for Windows imaging software (Tucsen, China). Each image  
201 was processed using a sharpen filter and contrast and brightness  
202 adjustment only. All photomicrographic plates were made using  
203 Adobe Photoshop 6.0 software (Adobe Systems, USA).

204 To determine the percentage of NPY-IR profiles, we counted the total  
205 number of PGP-IR neurons in the measured area and considered them  
206 as 100%. NPY-IR neuronal profiles were counted in randomly selected  
207 measured areas (1 microscopic field was 0.12 mm<sup>2</sup>) at 200-fold magni-  
208 fication. To avoid duplicate counts of neurons in the serial sections of the  
209 ganglia, only those nerve cell bodies containing a clearly identified nucle-  
210 ulus were counted in any given section. Data from 10 measured areas  
211 per ganglion per age-group, per animal, were included in this study.  
212 Data from individual ganglia in each age-group were meaned yielding  
213 group sizes of  $n = 5$ .

214 The relative numbers of NPY-IR fibers (minimum length 50  $\mu$ m)  
215 were determined in randomly selected measured areas as was de-  
216 scribed for NPY-IR neuronal profiles.

217 Statistical methods include calculation of the mean and standard  
218 error of the mean. Differences in means were subjected to one-way  
219 ANOVA, followed by Tukey's post-test of multiple comparisons. Differ-  
220 ences were considered statistically significant if  $p < 0.05$ .

## 221 3. Results

222 Immunohistochemistry and Western blot analysis was used to label  
223 NPY, Y1R, Y2R, and Y5R in the heart tissue and intramural cardiac gan-  
224 glia from rats of different ages. There were no significant differences in  
225 the expression of NPY or its receptors between the left and right atria  
226 or left and right ventricles at particular time points. Therefore, the re-  
227 maining results represent pooled data for both the left and right heart.

### 228 3.1. Immunohistochemical studies of NPY and its receptors

#### 229 3.1.1. Development of NPY-IR nerve fibers in the heart


230 Immunohistochemistry was performed to investigate the pattern of  
231 NPY expression in the heart during rat postnatal development. NPY im-  
232 muno-reactivity was observed in the atria and ventricles of all studied  
233 animals from birth onwards (Fig. 1). Nerve bundles and individual var-  
234 icose nerve fibers were NPY-IR. Nerve fiber plexuses, immunoreactive  
235 for NPY, were present around blood vessels, and individual fibers  
236 were present between cardiomyocytes. The density of NPY-positive  
237 fibers was minimal in newborn animals and increased in the first  
238 20 days of life (Table 2). In the atria of newborn and 10-day-old  
239 rats, NPY-IR fibers were more abundant compared with the ventricles  
240 ( $p < 0.05$ ).

241 In newborns, only 62% of NPY-IR fibers colocalized TH. In 10-day-old  
242 and older rats, all (100%) NPY-IR fibers were also TH-IR. Some of the  
243 NPY-IR fibers also contained ChAT in the atria but not in the ventricles  
244 of young and old rats.

#### 245 3.1.2. Development of receptors to NPY in the heart tissue

246 Immunohistochemistry was performed in order to show the expres-  
247 sion and distribution of Y1R, Y2R, and Y5R in the heart. These receptor  
248 types were found in the atria and ventricles of newborn and more  
249 adult rats.

250 Y1R immunoreactivity was most distinct on the membrane of  
251 cardiomyocytes, with additional granular intracellular labeling. Density  
252 of Y1R significantly increased between 10 and 20 days of life (Fig. 2).  
253 Faint Y2R immunoreactivity was only observed in the atria and



**Fig. 1.** Fluorescence micrographs of NPY (green) and TH (red) immunoreactivity in the left atria of newborn (a), 10-day-old (b), 30-day-old (c), and 2-year-old (d) rats. NPY-IR fibers colocalizing TH are indicated by arrows. Bar, 50  $\mu$ m. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)



**Table 2**  
Density of NPY-IR fibers in the rat heart during the development (per mm<sup>2</sup>, n = 5 in each age-group).

Age	Atria	Ventricles
Newborn	78 ± 12,4**	34 ± 10,2
10 days old	368 ± 36,8**	252 ± 26,4
20 days old	526 ± 46,2*	470 ± 41,2*
1 month old	502 ± 35,6*	542 ± 44,6*
2 months old	494 ± 38,2*	509 ± 49,4*
1 year old	518 ± 29,0*	521 ± 26,4*
2 years old	487 ± 53,6*	514 ± 62,4*

\* p < 0.01, compared with newborn and 10-day-old rats.

\*\* p < 0.05, compared with ventricles.

ventricles of rats after 20 days of life (Fig. 3). Granules of Y2R were located in cardiomyocytes. The density of Y2R-IR granules increased in 30-day-old rats compared with 20-day-old rats and did not change during further development. In contrast, the highest level of the expression of Y5R was found in newborn pups compared with more adult rats (Fig. 4). In newborns, receptors were observed in the coronary vessels, cardiomyocytes and NPY-IR nerve fibers. In 10-day-old and older rats, Y5R were found mainly in NPY-IR nerves.

### 3.1.3. Immunohistochemistry of the cardiac intramural ganglia during post-natal development

NPY-IR neurons were observed in the cardiac intramural ganglia from birth onwards (Fig. 5). In these ganglia, the percentage of NPY-IR profiles significantly increased from the moment of birth (66 ± 5.3%) until 10 days of life, where the number of profiles became 98 ± 0.3% (p < 0.01) and did not change during further development. In 10-day-old and older rats, all NPY-IR intramural ganglionic neurons were also ChAT-IR.

In newborn rats, the vast majority (87 ± 4.6%) of NPY-IR neurons were also TH-IR. Further, the expression of TH was downregulated, and in 10-day-old rats, we did not observe TH-IR neurons in the intramural ganglia.

All neurons in the intramural ganglia also had Y1R and Y5R immunoreactivity. No Y2R-IR profiles were observed in the ganglia during the development.

### 3.2. Expression of NPY and receptors to NPY by Western blot analysis

In order to further measure the protein expressions of three NPY receptor subtypes, total protein extracted from atria and ventricles were subjected to Western blot analysis. Fig. 6 showed the data of specific antibodies probed to NPY, Y1R, Y2R, and Y5R, in which the targeted bands were 11, 43, 42, and 52 kDa, respectively, using immunoblot.


NPY was expressed in newborn and 10-day-old rats at a low level (Fig. 7). Its expression significantly increased between 10 and 20 days (p < 0.05). The level of NPY expression in the atria was larger compared with ventricles in newborn and 10-day-old rats (p < 0.05).

The expression of Y1R, Y2R, and Y5R did not differ in atria compared with ventricles in all studied age-groups (p > 0.05). The expression of Y1R was low in newborn and 10-day-old rats and was upregulated in next 10 days of life (p < 0.05). Further, we did not find statistically significant differences between 20-day-old and older rats (p > 0.05).


The expression of Y2R was not observed in newborn and 10-day-old animals and appeared only in 20-day-old rats. The expression of Y2R increased in 30-day-old rats compared with 20-day-old (p < 0.05) and did not change later during development and senescence.

The expression of Y5R was maximal in newborn pups and significantly decreased in the first 10 days (p < 0.05). No statistically significant differences were found between 10-day-old and older age-groups (p > 0.05).

Among all types of receptors, Y5R had the highest level of expression in newborns. In 20-day-old and older rats, the expression of Y1R prevailed. The ratio of Y1R to Y5R expression was 0.8 in newborns and raised to 3.0–3.1 in 20-day-old and older rats. Y1R/Y2R ratio was 3.0 in 20-day-old rats and 2.0 in animals after 30 days of life. The relation of Y2R/Y5R was 1.4–1.5 in 20-day-old and older rats.



**Fig. 2.** Fluorescence micrographs of NPY (green) and Y1R (red) immunoreactivity in the left atria of newborn (a), 10-day-old (b), 30-day-old (c), and 2-year-old (d) rats. Bar, 50  $\mu$ m. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)



**Fig. 3.** Fluorescence micrographs of NPY (green) and Y2R (red, arrows) immunoreactivity in the left ventricles of 20-day-old (a) and 2-year-old (b) rats. Bar, 50  $\mu\text{m}$ . (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

#### 309 4. Discussion

310 The present study shows changes in the expression of NPY, Y1R, Y2R,  
311 and Y5R in the rat heart during postnatal development.


312 The autonomic innervation of the cardiovascular system in rats is  
313 immature at birth and reaches adult characteristics between the 5th  
314 and 8th week of life (Kuncova and Slavikova, 2000). Biochemical and  
315 morphological works confirmed that sympathetic innervation of the  
316 newborn rat heart is poor developed at birth (De Champlain et al.  
317 1970; Pappano, 1977). In newborn rats, we observed a small amount  
318 of NPY-IR fibers. The density of NPY-positive fibers increases in the  
319 first 20 days of rats' life. An increase of NPY-IR sympathetic ganglionic  
320 neurons is observed at the same period (Maslyukov et al. 2007, 2010;  
321 Masliukov et al. 2012; Masliukov and Nozdrachev 2013).

322 The majority of NPY-IR fibers are postganglionic sympathetic fibers,  
323 originating from the stellate ganglion neurons (Richardson et al. 2006;  
324 Masliukov et al. 2012). We also found many NPY-IR fibers colocalizing  
325 TH, the enzyme of catecholamine synthesis, from birth onwards. How-  
326 ever, there is a delay in co-localization of NPY and TH in sympathetic

327 fibers. In newborn, some NPY-IR fibers are TH-negative. NPY in new-  
328 born sympathetic fibers is particularly important due to its possible  
329 trophic action. Some studies indicate that NPY plays a critical role as a  
330 mediator of the innervation-dependent change in  $\alpha$ 1-adrenoceptor-  
331 dependent chronotropic responsiveness (Sun et al. 1991, 1998) and  
332 also promotes growth of cardiomyocytes and capillaries (Pellieux et al.  
333 2000; Movafagh et al. 2006). In the atria, some of the NPY-IR fibers are  
334 also cholinergic originating from intramural ganglionic neurons and  
335 expressing ChAT.


336 Previous studies have shown that the right atrium receives the  
337 predominant sympathetic innervation to the neonatal rat heart (De  
338 Champlain et al. 1970). We did not find statistically significant differ-  
339 ences between the densities of NPY-IR fibers in the right and left atria.  
340 However, the density of NPY-IR fibers was larger in the atria comparing  
341 with the ventricles in young rats.

342 Horackova et al. (2000) did not find NPY-IR neurons in the intramu-  
343 ral ganglia of the heart during the first 2 weeks of postnatal develop-  
344 ment. However, we observed that NPY immunoreactivity is exist in  
345 small number of ganglionic neurons even at birth and their number



**Fig. 4.** Fluorescence micrographs of NPY (green) and Y5R (red) immunoreactivity in the left atria of newborn (a), 10-day-old (b), 30-day-old (c), and 2-year-old (d) rats. NPY-IR fibers colocalizing Y5R are indicated by arrows. Bar, 50  $\mu\text{m}$ . (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)





**Fig. 5.** Fluorescence micrographs of NPY-IR neurons (a, c, d—green, b—red) colocalizing TH (red, a), ChAT (green, b), Y1R (red, c), and Y5R (red, d) in intramural ganglia of the right atrium of newborn (a, b) and 2-month-old (c, d) rats. NPY-negative neurons are indicated by arrows. Bar, 50  $\mu$ m. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

rapidly increased during first 10 days of life. Some authors also identified NPY-IR neurons in the heart of newborn rats (Nyquist-Battie et al. 1994). Possibly, these disagreements can be caused by the small amount of NPY in the ganglionic neurons of newborn animals and different sensitivity of antibodies used in the above mentioned works.

The percentage of NPY-IR neurons in the intramural ganglia of the heart significantly increased in the first 10 days of the development. Only in newborn animals the vast majority of NPY-IR neurons also

expressed TH. Our results are consistent with other studies in the rat (Horackova et al. 1990; Richardson et al. 2003; Slavikova et al., 1993).


We focused on Y1R, Y2R, and Y5R because they are most abundant in the heart of adult rats (Protas et al. 2003; Masliukov and Nozdrachev 2013). Western blot analysis verified the results we got from immunohistochemistry. A downregulated level of Y5R and a reverse trend in Y1R and Y2R were clearly observed in the heart tissue.

In newborn and 10-day-old rats, only small number of Y1R was found by means of immunohistochemistry and Western blot analysis. However, Y1R was upregulated in the next 10 days, and a high level of Y1R in the heart tissue was observed in 20-day-old and older rats. Previous reports show that in the rat heart, the expression of Y1R is dominates over Y2R (Chottová Dvoráková et al. 2008). We also found lower level of Y2R expression compared with Y1R. Y2R were found at low level only in 20-day-old and older rats.


In the human heart, immunohistochemistry localized both the Y1R and the Y2R subtype on nerve fiber bundles, conducting fibers of the atrioventricular node, and some but not all arterioles and atrial and ventricular cardiomyocytes (Jönsson-Rylander et al. 2003). A positive contractile effect of NPY is mediated by Y1R, whereas a negative contractile effect is mediated by Y2R (McDermott et al., 1997).

We first noticed Y5R-IR in the rat heart during the development by immunohistochemistry and Western blot analysis. We found that Y5R was downregulated in the first 10 days. In young and adult rats, Y5R were located primarily in the NPY-IR nerve fibers. Developmental changes of Y5R were also found in the central nervous system, where Y5R inhibited synaptic excitation in the hippocampal slice only in young rats and their contribution declined with age (Ho et al. 2000).

NPY acts as a trophic factor by promoting growth and/or differentiation of a variety of cells in a receptor-specific manner. The hypertrophic effect of NPY is accompanied by increased activity of cytosolic creatine kinase, protein kinase C, and protein kinase C-dependent activation of mitogen activated protein kinase in adult and neonatal myocytes and activation of phosphoinositol 3-kinase in adults (Protas et al. 2003).



**Fig. 6.** The representative immunoblot bands of NPY, Y1R, Y2R, Y5R and GAPDH in the left atria of newborn, 10-day-old, 20-day-old, and 30-day-old rats by Western blot.



**Fig. 7.** The data analysis of NPY, Y1R, Y2R, and Y5R expression in the atria (A) and ventricles (B) by Western blot. All data represented a relative quantification to internal control GAPDH. \* $p < 0.05$  compared to newborns. † $p < 0.05$  compared to 20-day-old rats.

389 Via its Y1R, Y2R, and Y5R, NPY promotes angiogenesis (Kuo et al. 418  
390 2007; Parker and Balasubramaniam 2008; Zhang et al. 2015), where 419  
391 the Y5R acts as an enhancer (Movafagh et al. 2006). In rats, the 420  
392 transmural number of capillaries in the left ventricle increases 3-fold 421  
393 from 1 to 5 days and 5-fold from 1 to 11 day of life. At 11 days, the 422  
394 capillary density in the myocardium is comparable to that in adult myocar- 423  
395 dium (Anversa et al. 1978; Olivetti et al. 1980). By our data, the highest 424  
396 level of expression had Y5R in the first 10 days of age. We could suggest 425  
397 that during early development Y5R have the most important role in 426  
398 stimulating blood vessels growth.

399 The expression of the Y5R was detected in primary cultured 427  
400 cardiomyocytes of mouse by reverse transcriptase-polymerase chain 428  
401 reaction (Pellieux et al. 2000). The growth stimulating effect of Y5R activa- 429  
402 tion leads to increased protein kinase C activity, cAMP inhibition and to 430  
403 mitogen activated protein kinase phosphorylation and activity (Pellieux 431  
404 et al. 2000; Sheriff et al. 2010). The activation of mitogen-activated pro- 432  
405 tein kinase appears could be important in the intracellular-signaling 433  
406 pathways leading to growth-promoting effects of cardiomyocytes in sit- 434  
407 uations of low sympathetic activity in newborns. 435

408 In rats, the cardiac  $\alpha$ 1-adrenergic chronotropic response changes 436  
409 from stimulatory to inhibitory postnatally (Drugge et al. 1985). In 437  
410 vitro studies indicate that neurally released NPY plays a critical role in 438  
411 the innervation-dependent maturation of the  $\alpha$ -adrenergic response 439  
412 (Sun et al. 1991, 1998; Robinson 1996). Sun et al. (1998) suggested 440  
413 that the Y2R or “peptide YY preferring” is the subtype likely mediating 441  
414 the trophic effect of NPY on  $\alpha$ -adrenergic signaling in the neonatal rat 442  
415 ventricles. However, our data indicate that Y2R do not express in the 443  
416 heart of newborn rats. It seems that commercially available NPY peptide 444  
417 receptor agonists may not be adequate tools for assessing the role of

specific NPY receptor subtypes in vitro. The limitation of this approach 418  
is that peptide fragments bind NPY receptors with low nanomolar affin- 419  
ities and therefore can be classified as “receptor preferring” but are not 420  
strictly receptor selective (Guo et al. 2002). NPY 13–36, used in the study 421  
of Sun et al. (1998) as Y2R agonist at a concentration of  $10^{-7}$  M, may 422  
react with Y2R and also with Y5R (Gerald et al. 1996). Therefore, further 423  
pharmacological studies with more selective agonists of Y2R and Y5R 424  
are required. 425

426 Thus, in the heart of newborn rat, NPY may play a trophic function 427  
via Y5R promoting growth of cardiomyocytes and myocardial capil- 428  
laries. This type of receptors may be very important at the period of 429  
rapid increasing of the heart weight and establishing of sympathetic 430  
innervation.

431 We did not find differences on the expression of NPY, Y1R, Y2R, and 432  
Y5R between young (1- and 2-month-old) and aged (24-month-old) 433  
rats. These data confirm our earlier observations about constancy of 434  
the number of sympathetic NPY-IR neurons during aging (Masliukov 435  
et al. 2012). Therefore, NPY-ergic system of the rat heart regulation is 436  
transformed in the first 20 days of life and remains stable throughout 437  
the senescence. 438

## 5. Conclusion 438

439 Thus, the increasing of density of NPY-containing nerve fibers ac- 440  
companies changes in relation of different subtypes of NPY receptors 441  
in the heart during development. In the rat heart, Y1R and Y2R expres- 442  
sion is upregulated, whereas Y5R expression is downregulated during 443  
the development. Further physiological and pharmacological studies 444  
using selective agonists and antagonists of NPY receptors are required



445 to understand better the function NPY during the development. The in-  
446 formation provided here further serves as a basis for future studies in-  
447 vestigating the mechanisms of development of autonomic regulation.

### Q13 Uncited references

- 449 [Decressac et al., 2009](#)  
450 [Hansel et al., 2001](#)  
451 [Tyrrell and Landis, 1994](#)  
452 [Tyrrell et al., 1992](#)  
453 [Xu et al., 2014](#)

### 454 Acknowledgments

455 This work was supported by the Russian Foundation for Basic Re-  
456 search (grant no. 13-04-00059).

### 457 References

- 458 Allen, A.R., Kelso, E.J., Bell, D., Zhao, Y., Dickson, P., McDermott, B.J., 2006. Modulation of  
459 contractile function through neuropeptide Y receptors during development of cardio-  
460 myocyte hypertrophy. *J. Pharmacol. Exp. Ther.* 319, 1286–1296.  
461 Anversa, P., Loud, A.V., Giacomelli, F., Wiener, J., 1978. Absolute morphometric study of  
462 myocardial hypertrophy in experimental hypertension. II. Ultrastruc. myocytes and  
463 interstitium. *Lab. Invest.* 38, 597–609.  
464 Balasubramaniam, A.A., 1997. Neuropeptide Y family of hormones: receptor subtypes and  
465 antagonists. *Peptides* 18, 445–457.  
466 Chottová Dvoráková, M., Wiegand, S., Pesta, M., Slavíková, J., Grau, V., Reischig, J.,  
467 Kuncová, J., Kummer, W., 2008. Expression of neuropeptide Y and its receptors Y1  
468 and Y2 in the rat heart and its supplying autonomic and spinal sensory ganglia in ex-  
469 perimentally induced diabetes. *Neuroscience* 151, 1016–1028.  
470 De Champlain, J., Malmfors, T., Olson, L., Sachs, C., 1970. Ontogenesis of peripheral adre-  
471 nergic neurons in the rat: pre- and post-natal observations. *Acta Physiol. Scand.* 80,  
472 276–288.  
473 Decressac, M., Prestoz, L., Veran, J., Cantereau, A., Jaber, M., Gaillard, A., 2009. Neuropep-  
474 tide Y stimulates proliferation, migration and differentiation of neural precursors  
475 from the subventricular zone in adult mice. *Neurobiol. Dis.* 34, 441–449.  
476 Drugge, E.D., Rosen, M.R., Robinson, R.B., 1985. Neuronal regulation of the development of  
477 the cardiac alpha adrenergic chronotropic response. *Circ. Res.* 57, 415–423.  
478 Gerald, C., Walker, M.W., Criscione, L., Gustafson, E.L., Batzl-Hartmann, C., Smith, K.E.,  
479 Vaysse, P., Durkin, M.M., Laz, T.M., Linemeyer, D.L., Schaffhauser, A.O., Whitebread,  
480 S., Hofbauer, K.G., Taber, R.L., Branchek, T.A., Weinschank, R.L., 1996. A receptor sub-  
481 type involved in neuropeptide-Y-induced food intake. *Nature* 382, 168–171.  
482 Guo, H., Castro, P.A., Palmiter, R.D., Baraban, S.C., 2002. Y5 receptors mediate neuropep-  
483 tide Y actions at excitatory synapses in area CA3 of the mouse hippocampus.  
484 *J. Neurophysiol.* 87, 558–566.  
485 Hansel, D.E., Eipper, B.A., Ronnett, G.V., 2001. Neuropeptide Y functions as a  
486 neuroproliferative factor. *Nature* 410, 940–944.  
487 Ho, M.W.Y., Beck-Sickinger, A.G., Colmers, W.F., 2000. Neuropeptide Y5 receptors reduce  
488 synaptic excitation in proximal tubulum, but not epileptiform activity in rat hippo-  
489 campal slices. *J. Neurophysiol.* 83, 723–734.  
490 Hodges, G.J., Jackson, D.N., Mattar, L., Johnson, J.M., Shoemaker, J.K., 2009. Neuropeptide Y  
491 and neurovascular control in skeletal muscle and skin. *Am. J. Physiol. Regul. Integr.*  
492 *Comp. Physiol.* 297, 546–555.  
493 Horackova, M., Slavikova, J., Byczko, Z., 2000. Postnatal development of the rat intrinsic  
494 cardiac nervous system: a confocal laser scanning microscopy study in whole-  
495 mount atria. *Tissue Cell* 32, 377–388.  
496 Jönsson-Rylander, A.C., Nordlander, M., Svindland, A., Ilebekk, A., 2003. Distribution of  
497 neuropeptide Y Y1 and Y2 receptors in the postmortem human heart. *Peptides* 24,  
498 255–262.  
499 Kageyama, H., Takenoya, F., Hirako, S., Wada, N., Kintaka, Y., Inoue, S., Ota, E., Ogawa, T.,  
500 Shioda, S., 2012. Neuronal circuits involving neuropeptide Y in hypothalamic arcuate  
501 nucleus-mediated feeding regulation. *Neuropeptides* 46, 285–289.  
502 Kassiss, S., Olasmaa, M., Terenius, L., Fishman, P.H., 1987. Neuropeptide Y inhibits cardiac  
503 adenylate cyclase through a pertussis toxin-sensitive G-protein. *J. Biol. Chem.* 262,  
504 3429–3431.  
505 Kuo, L.E., Kitlinska, J.B., Tilan, J.U., Li, L., Baker, S.B., Johnson, M.D., Lee, E.W., Burnett, M.S.,  
506 Fricke, S.T., Kvetnansky, R., Herzog, H., Zukowska, Z., 2007. Neuropeptide Y acts di-  
507 rectly in the periphery on fat tissue and mediates stress-induced obesity and meta-  
508 bolic syndrome. *Nat. Med.* 13, 803–811.  
509 Masliukov, P.M., Nozdrachev, A.D., 2013. Developmental role of neuropeptide Y in the au-  
510 tonomic ganglia. In: Parker, S.L. (Ed.), *Neuropeptide Y: Molecular Structure, Role in*  
511 *Food Intake and Direct/Indirect Effects*. Nova Science Publishers, pp. 83–106.  
512 Masliukov, P.M., Konovalov, V.V., Emanuilov, A.I., Nozdrachev, A.D., 2012. Development of  
513 neuropeptide Y-containing neurons in sympathetic ganglia of rats. *Neuropeptides* 46,  
514 345–352.  
515 Masliukov, P.M., Emanuilov, A.I., Moiseev, K., Nozdrachev, A.D., Dobrotvorskaya, S.,  
516 Timmermans, J.P., 2015. Development of non-catecholaminergic sympathetic  
517 neurons in para- and prevertebral ganglia of cats. *Int. J. Dev. Neurosci.* 40,  
518 76–84.

- Masliukov, P.M., Nozdrachev, A.D., Timmermans, J.P., 2007. Age-related characteristics of  
519 the neurotransmitter composition of neurons in the stellate ganglion. *Neurosci.*  
520 *Behav. Physiol.* 37, 349–353.  
521 Masliukov, P.M., Korzina, M.B., Emanuilov, A.I., Shilkin, V.V., 2010. Neurotransmitter com-  
522 position of neurons in the cranial cervical and celiac sympathetic ganglia in postnatal  
523 ontogenesis. *Neurosci. Behav. Physiol.* 40, 143–147.  
524 Michel, M.C., Beck-Sickinger, A., Cox, H., Doods, H.N., Herzog, H., Larhammar, D., Quirion,  
525 R., Schwartz, T., Westfall, T., 1998. XVI. International Union of Pharmacology recom-  
526 mendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic  
527 polypeptide receptors. *Pharmacol. Rev.* 50, 143–150.  
528 Millar, B.C., Weis, T., Piper, H.M., Weber, M., Borchard, U., McDermott, B.J., Balasubramaniam,  
529 A., 1991. Positive and negative contraction effects of neuropeptide Y on ventricular  
530 cardiomyocytes. *Am. J. Physiol.* 261, H1727–H1733.  
531 Movafagh, S., Hobson, J.P., Spiegel, S., Kleinman, H.K., Zukowska, Z., 2006. Neuropeptide Y  
532 induces migration, proliferation, and tube formation of endothelial cells bimodally via  
533 Y1, Y2, and Y5 receptors. *FASEB J.* 20, 1924–1926.  
534 Nozdrachev, A.D., Masliukov, P.M., 2011. Neuropeptide Y and autonomic nervous system.  
535 *Zh. Evol. Biokhim. Fiziol.* 47, 105–112.  
536 Nyquist-Battie, C., Cochran, P.K., Sands, S.A., Chronwall, B.M., 1994. Development of neu-  
537 ropeptide Y and tyrosine hydroxylase immunoreactive innervation in postnatal rat  
538 heart. *Peptides* 15, 1461–1469.  
539 Olivetti, G., Anversa, P., Loud, A.V., 1980. Morphometric study of early postnatal develop-  
540 ment in the left and right ventricular myocardium of the rat. II. Tissue composition,  
541 capillary growth, and sarcoplasmic alterations. *Circ. Res.* 46, 503–512.  
542 Parker, S.L., Balasubramaniam, A., 2008. Neuropeptide Y Y2 receptor in health and disease.  
543 *Br. J. Pharmacol.* 153, 420–431.  
544 Pellieux, C., Sauthier, T., Domenighetti, A., Marsh, D.J., Palmiter, R.D., Brunner, H.R.,  
545 Pedrazzini, T., 2000. Neuropeptide Y (NPY) potentiates phenylephrine-induced  
546 mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5  
547 receptors. *Proc. Natl. Acad. Sci. U. S. A.* 97, 1595–1600.  
548 Piper, H.M., Millar, B.C., McDermott, B.J., 1989. The negative inotropic effect of neuropep-  
549 tide Y on the ventricular cardiomyocyte. *Naunyn Schmiedeberg's Arch. Pharmacol.*  
550 340, 333–337.  
551 Protas, L., Qu, J., Robinson, R.B., 2003. Neuropeptide Y: neurotransmitter or trophic factor  
552 in the heart? *News physiol. Sci.* 18, 181–185.  
553 Richardson, R.J., Grkovic, I., Anderson, C.R., 2003. Immunohistochemical analysis of intra-  
554 cardiac ganglia of rat heart. *Cell Tissue Res.* 314, 337–350.  
555 Richardson, R.J., Grkovic, I., Allen, A.M., Anderson, C.R., 2006. Separate neurochemical clas-  
556 ses of sympathetic postganglionic neurons project to the left ventricle of the rat heart.  
557 *Cell Tissue Res.* 324, 9–16.  
558 Robinson, R.B., 1996. Autonomic receptor–effector coupling during post-natal develop-  
559 ment. *Cardiovasc. Res.* 31, E68–E76.  
560 Sheriff, S., Ali, M., Yahya, A., Haider, K.H., Balasubramaniam, A., Amlal, H., 2010. Neuropep-  
561 tide Y5 receptor promotes cell growth through extracellular signal-regulated kinase  
562 signaling and cyclic AMP inhibition in a human breast cancer cell line. *Mol. Cancer*  
563 9, 604–614.  
564 Shoba, T., Tay, S.S.W., 2000. Nitroergic and peptidergic innervation in the developing rat  
565 heart. *Anat. Embryol.* 201, 491–500.  
566 Slavikova, J., Goldstein, M., Dahlstrom, A., 1993. The postnatal development of tyrosine  
567 hydroxylase immunoreactive nerves in rat atrium, studied with immunofluorescence  
568 and confocal laser scanning microscopy. *J. Auton. Nerv. Syst.* 43, 159–170.  
569 Sun, L.S., Ursell, P.C., Robinson, R.B., 1991. Chronic exposure to neuropeptide Y determines  
570 cardiac alpha1 adrenergic responsiveness. *Am. J. Physiol.* 261, H969–H973.  
571 Sun, L.S., Rybin, V.O., Steinberg, S.F., Robinson, R.B., 1998. Characterization of the alpha1-  
572 adrenergic chronotropic response in neuropeptide Y-treated cardiomyocytes. *Eur.*  
573 *J. Pharmacol.* 349, 377–381.  
574 Tatamoto, K., 1982. Neuropeptide Y. Complete amino acid sequence of the brain peptide.  
575 *Proc. Natl. Acad. Sci. U. S. A.* 79, 5485–5489.  
576 Tatamoto, K., Carlquist, M., Mutt, V., 1982. Neuropeptide Y—a novel brain peptide with  
577 structural similarities for peptide YY and pancreatic polypeptide. *Nature* 296,  
578 659–660.  
579 Tyrrell, S., Landis, S.C., 1994. The appearance of NPY and VIP in sympathetic neuroblasts  
580 and subsequent alterations of their expression. *J. Neurosci.* 14, 4529–4547.  
581 Tyrrell, S., Siegel, R.E., Landis, S.C., 1992. Tyrosine hydroxylase and neuropeptide Y are in-  
582 creased in ciliary ganglia of sympathotomized rats. *Neuroscience* 47, 985–998.  
583 Valder, C.R., Liu, J.J., Song, Y.H., Luo, Z.D., 2003. Coupling gene chip analyses and rat genetic  
584 variances in identifying potential target genes that may contribute to neuropathic  
585 allodynia development. *J. Neurochem.* 87, 560–573.  
586 Wakisaka, S., Kajander, K.C., Bennett, G.J., 1991. Increased neuropeptide (NPY)-like immu-  
587 noreactivity in rat sensory neurons following peripheral axotomy. *Neurosci. Lett.* 124,  
588 200–203.  
589 Walther, C., Mörl, K., Beck-Sickinger, A.G., 2011. Neuropeptide Y receptors: ligand binding  
590 and trafficking suggest novel approaches in drug development. *J. Pept. Sci.* 17, 233–246.  
591 Xu, X., Guo, F., He, Q., Cai, X., Min, D., Wang, Q., Wang, S., Tian, L., Cai, J., Zhao, Y., 2014. Al-  
592 tered expression of neuropeptide Y, Y1 and Y2 receptors, but not Y5 receptor, within  
593 hippocampus and temporal lobe cortex of tremor rats. *Neuropeptides* 48, 97–105.  
594 Young, H.M., Cane, K.N., Anderson, C.R., 2011. Development of the autonomic nervous  
595 system: a comparative view. *Auton. Neurosci.* 165, 10–27.  
596 Zhang, P., Qi, Y.X., Yao, Q.P., Chen, X.H., Wang, G.L., Shen, B.R., Han, Y., Gao, L.Z., Jiang, Z.L.,  
597 2015. Neuropeptide Y stimulates proliferation and migration of vascular smooth  
598 muscle cells from pregnancy hypertensive rats via Y1 and Y5 receptors. *PLoS One*  
599 10, e0131124.  
600 Zukowska-Projec, Z., Karwatowska-Prokoczuk, E., Rose, W., Rone, J., Movafagh, S., Ji, H.,  
601 Yeh, Y., Chen, W.T., Kleinman, H.K., Grouzmann, E., Grant, D.S., 1998. Neuropeptide Y:  
602 a novel angiogenic factor from the sympathetic nerves and endothelium. *Circ. Res.* 83,  
603 187–195.  
604